Video Archives

Cognitive Bias in Practice and Training

Posted by Justin J. Badal, MD | Jul 2024

Justin J. Badal, MD, examines the impact of cognitive bias in medical training and practice on clinical decision-making, diagnostic accuracy, and patient outcomes. He begins by defining cognitive bias, and analyzing common biases, including:

Representativeness Bias
Misconception of Regression Bias
Availability Bias
Adjustment and Anchoring Bias

Dr. Badal demonstrates examples of the impact of each bias in diagnostic testing, clinical decision-making, and patient outcomes. He concludes by making recommendations for counteracting cognitive bias in practice with evidence that bias training improves overall clinician performance.

Success with Sacral Neuromodulation

Posted by Robert J. Evans, MD, FACS | Jul 2024

Robert J. Evans, MD, FACS, provides practical guidance on successfully incorporating sacral neuromodulation (SNM) into a urology practice. He begins by discussing proper documentation strategies to avoid SNM being rejected by insurance.

Dr. Evans then shares his approach to patient education and engagement. He presents the available options for SNM devices and implantation procedures. He outlines the ideal patient profile for staged versus peripheral nerve evaluation procedures, and he discusses the level of patient engagement required for rechargeable versus non-rechargeable SNM devices.

Dr. Evans concludes by providing guidance on troubleshooting. He presents common technical issues and patient experiences with SNM devices. For each issue, he presents solutions which can be implemented in-office.

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options

Posted by E. David Crawford, MD | Jul 2024

E. David Crawford, MD, Stephen Kaplan, MD, and Kevin T. McVary, MD, FACS, explore the utility of the Optilume® BPH Catheter System, a novel minimally-invasive surgical therapy (MIST). This is the second in a series supported by Laborie.

Dr. McVary begins with an overview of the current BPH market, diagnostic, and treatment algorithms and pharmaceutical/surgical treatment pathways. He illustrates the growing population of men with BPH who are underserved by pharmaceuticals, and those who are concerned about long-term effects of medication on their sexual function. Additionally, he discusses the dangers of delaying surgical management when it is indicated.

Dr. Kaplan then compares the function and outcomes of the Optilume® BPH Catheter System to those of current MIST and invasive surgeries. With an emphasis on the preservation of sexual function and low intraoperative risk, Dr. Kaplan and Dr. McVary discuss the clinical data, their experience with using the Optilume® BPH Catheter System, and their expectations for real-world data.

To see the Thought Leader Q&A session on this topic, click here [link to Q+A on GRU]. To see the first part of this series, click here. For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

High-Risk Localized and Oligometastatic Disease

Posted by Christopher J. Kane, MD, FACS | Jul 2024

Christopher J. Kane, MD, FACS, provides an overview of current best practices in detecting and treating high-risk localized and oligometastatic prostate cancer. In this presentation, he reviews:
The diagnostic value of PSMA PET versus nodal dissection
The overall survival rates of patients treated with ADT plus XRT versus ADT alone
The risks of long-term ADT

Life Expectancy as It Relates to the Treatment of Urologic Cancers

Posted by Thomas W. Jarrett, MD | Jul 2024

Thomas W. Jarrett, MD, discusses the impact of life expectancy on urologic cancer treatment and management in the United States. He begins by highlighting outdated life expectancy models and the importance of assessing life expectancy prior to exploring treatment options.

Dr. Jarrett then discusses the traditional methods of assessing life expectancy and their failure to account for patient comorbidities. He lists the most significant comorbidities which impact life expectancy according to their hazard score.

Dr. Jarrett then addresses overall trends in life expectancy in the United States. He notes that life expectancy sharply decreased during COVID-19 and that the United States has yet to recover compared to European life expectancy trends.

Dr. Jarrett concludes by illustrating the influence of perceived life expectancy on urologic cancer management and outcomes. He discusses the impact of life expectancy on treatment options for urothelial cancer, testicular cancer, renal cancer, and prostate cancer.